FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2539341441> ?p ?o ?g. }

• W2539341441 abstract "Abstract Abstract 881 Background. The Japan Clinical Oncology Group (JCOG)-Lymphoma Study Group (LSG) conducted 3 clinical trials in the 1990s for aggressive ATL, i.e. acute, lymphoma, and unfavorable chronic types, associated with human T-lymphotropic virus type-I. The prognosis of aggressive ATL patients (pts) is still poor, but the 5-year survival rate was improved from 5% in the 1980s to 15% in a JCOG study in late 1990s. To characterize long-term survivors and to develop a new predictive model for aggressive ATL, we performed a combined analysis of enrolled pts in the 3 JCOG studies. Methods. A total 276 pts with aggressive ATL were registered in 3 consecutive JCOG-LSG trials exclusively against aggressive ATL, i.e. JCOG9109, a phase II (pII) study of LSG11 consisting of pentostatin, VCR, ETP, PSL and DOX; JCOG9303, a pII study of LSG15 consisting of VCAP-AMP-VECP; and JCOG9801, a pIII study comparing modified (m) LSG15 with CHOP-14. The pts were analyzed for their prognosis, the effects of central nervous system (CNS) prophylaxis in the protocol treatment and allogeneic hematopoietic cell transplantation (allo-HCT) after the protocol treatment, and the outcome of long-term survivors with a follow-up survey. To build a predictive index, multivariate analyses with a Cox proportional hazard model were conducted using the test sample of 193 pts without missing covariate data from the entire cohort of 276 pts. Validation was carried out using external data for 136 pts, who were independent from those included in the JCOG studies. Results. The MST, 5- and 8-yesr OS rates of the entire cohort of 276 pts were 10.9 months, 13.6% and 10.0%, respectively. The median and longest follow-up periods were 10.9 months and 17.5 years, respectively. The differences of CNS prophylaxis by each regimen did not significantly affect the CNS relapse rate. We analyzed 269 eligible pts (acute 170, lymphoma 78, chronic 21). In 67 pts who survived for more than 2 years, there were 38 (22%) pts with acute type, 21 (28%) with lymphoma type and 5 (24%) with chronic type. The major proportion of relapse in pts with acute type occurred within 2 years after initiating chemotherapy, and occurred earlier than in pts with other types. In 37 pts who survived for more than 5 years (acute 22 (13%), lymphoma 8 (10%), chronic 7 (33%)), there were no disease-related deaths among lymphoma type pts, which was in contrast to the 10 disease-related deaths that occurred in pts with acute or chronic type during the follow-up period. The numbers of pts achieving CR and the other response category at the end of the protocol treatment were 24 and 13 in the 37 pts who survived for more than 5 years, respectively, and 11 and 1 in the 12 who survived for more than 10 years, respectively. Six of the 37 pts who survived for more than 5 years and 2 of 12 who survived for more than 10 years had received allo-HCT. In a test sample of 193 pts, two unfavorable factors associated with OS, high calcium (Ca) level and ECOG performance status (PS) of 2 to 4, were identified. The hazard ratio (HR) [95% confidence interval (CI)] of Ca and PS were 1.574 [1.09–2.28] and 1.554 [1.12–2.16], respectively. Considering the potential for clinical usage, four categories using these two factors were combined into a predictive index with 2 strata, thus resulting in pts with both Ca<5.5 mEq/l and PS 0, 1, and 7.9 months, 3.7% and 2.5% in those with Ca>=5.5 mEq/l and/or PS 2 to 4, respectively (Fig 1). The HR [95% CI] was 1.926 [1.42–2.61]. The predictive model was reproducible in the validation set. Conclusion. There were no disease-related deaths in 8 lymphoma type pts who survived for more than 5 years, suggesting that about 10% of pts with lymphoma type may be curable. We developed a predictive model for aggressive ATL based on Ca and PS, however, the MST was only 14.3 months even in the better prognostic group. To further improve the outcome, a pII trial of VCAP-AMP-VECP followed by allo-HCT (JCOG0907) and a randomized pII study of VCAP-AMP-VECP with or without anti-CCR4 antibody are underway. Disclosures: No relevant conflicts of interest to declare." @default.
• W2539341441 created "2016-10-28" @default.
• W2539341441 creator A5002493998 @default.
• W2539341441 creator A5004040407 @default.
• W2539341441 creator A5005125682 @default.
• W2539341441 creator A5007429494 @default.
• W2539341441 creator A5026907664 @default.
• W2539341441 creator A5034245076 @default.
• W2539341441 creator A5036000764 @default.
• W2539341441 creator A5038965321 @default.
• W2539341441 creator A5046859907 @default.
• W2539341441 creator A5048061147 @default.
• W2539341441 creator A5049201693 @default.
• W2539341441 creator A5049465924 @default.
• W2539341441 creator A5053647194 @default.
• W2539341441 creator A5054856257 @default.
• W2539341441 creator A5059167270 @default.
• W2539341441 creator A5060637461 @default.
• W2539341441 creator A5065894192 @default.
• W2539341441 creator A5067399580 @default.
• W2539341441 creator A5076119019 @default.
• W2539341441 creator A5076762618 @default.
• W2539341441 creator A5091610904 @default.
• W2539341441 date "2011-11-18" @default.
• W2539341441 modified "2023-10-13" @default.
• W2539341441 title "Characterization of Long-Term Survivors and a Predictive Model for Aggressive Adult T-Cell Leukemia-Lymphoma (ATL): An Ancillary Study by the Japan Clinical Oncology Group, JCOG0902A" @default.
• W2539341441 doi "https://doi.org/10.1182/blood.v118.21.881.881" @default.
• W2539341441 hasPublicationYear "2011" @default.
• W2539341441 type Work @default.
• W2539341441 sameAs 2539341441 @default.
• W2539341441 citedByCount "3" @default.
• W2539341441 countsByYear W25393414412013 @default.
• W2539341441 countsByYear W25393414412014 @default.
• W2539341441 crossrefType "journal-article" @default.
• W2539341441 hasAuthorship W2539341441A5002493998 @default.
• W2539341441 hasAuthorship W2539341441A5004040407 @default.
• W2539341441 hasAuthorship W2539341441A5005125682 @default.
• W2539341441 hasAuthorship W2539341441A5007429494 @default.
• W2539341441 hasAuthorship W2539341441A5026907664 @default.
• W2539341441 hasAuthorship W2539341441A5034245076 @default.
• W2539341441 hasAuthorship W2539341441A5036000764 @default.
• W2539341441 hasAuthorship W2539341441A5038965321 @default.
• W2539341441 hasAuthorship W2539341441A5046859907 @default.
• W2539341441 hasAuthorship W2539341441A5048061147 @default.
• W2539341441 hasAuthorship W2539341441A5049201693 @default.
• W2539341441 hasAuthorship W2539341441A5049465924 @default.
• W2539341441 hasAuthorship W2539341441A5053647194 @default.
• W2539341441 hasAuthorship W2539341441A5054856257 @default.
• W2539341441 hasAuthorship W2539341441A5059167270 @default.
• W2539341441 hasAuthorship W2539341441A5060637461 @default.
• W2539341441 hasAuthorship W2539341441A5065894192 @default.
• W2539341441 hasAuthorship W2539341441A5067399580 @default.
• W2539341441 hasAuthorship W2539341441A5076119019 @default.
• W2539341441 hasAuthorship W2539341441A5076762618 @default.
• W2539341441 hasAuthorship W2539341441A5091610904 @default.
• W2539341441 hasConcept C126322002 @default.
• W2539341441 hasConcept C141071460 @default.
• W2539341441 hasConcept C143998085 @default.
• W2539341441 hasConcept C207103383 @default.
• W2539341441 hasConcept C2776913467 @default.
• W2539341441 hasConcept C2777408962 @default.
• W2539341441 hasConcept C2779338263 @default.
• W2539341441 hasConcept C2780815077 @default.
• W2539341441 hasConcept C2911091166 @default.
• W2539341441 hasConcept C44249647 @default.
• W2539341441 hasConcept C50382708 @default.
• W2539341441 hasConcept C71924100 @default.
• W2539341441 hasConcept C72563966 @default.
• W2539341441 hasConceptScore W2539341441C126322002 @default.
• W2539341441 hasConceptScore W2539341441C141071460 @default.
• W2539341441 hasConceptScore W2539341441C143998085 @default.
• W2539341441 hasConceptScore W2539341441C207103383 @default.
• W2539341441 hasConceptScore W2539341441C2776913467 @default.
• W2539341441 hasConceptScore W2539341441C2777408962 @default.
• W2539341441 hasConceptScore W2539341441C2779338263 @default.
• W2539341441 hasConceptScore W2539341441C2780815077 @default.
• W2539341441 hasConceptScore W2539341441C2911091166 @default.
• W2539341441 hasConceptScore W2539341441C44249647 @default.
• W2539341441 hasConceptScore W2539341441C50382708 @default.
• W2539341441 hasConceptScore W2539341441C71924100 @default.
• W2539341441 hasConceptScore W2539341441C72563966 @default.
• W2539341441 hasLocation W25393414411 @default.
• W2539341441 hasOpenAccess W2539341441 @default.
• W2539341441 hasPrimaryLocation W25393414411 @default.
• W2539341441 hasRelatedWork W1239554424 @default.
• W2539341441 hasRelatedWork W2154316358 @default.
• W2539341441 hasRelatedWork W2474913972 @default.
• W2539341441 hasRelatedWork W2531743631 @default.
• W2539341441 hasRelatedWork W2542015896 @default.
• W2539341441 hasRelatedWork W2552384857 @default.
• W2539341441 hasRelatedWork W2555678589 @default.
• W2539341441 hasRelatedWork W2564514339 @default.
• W2539341441 hasRelatedWork W2576806401 @default.
• W2539341441 hasRelatedWork W2580785550 @default.
• W2539341441 hasRelatedWork W2582014052 @default.
• W2539341441 hasRelatedWork W2582467353 @default.
• W2539341441 hasRelatedWork W2586427173 @default.
• W2539341441 hasRelatedWork W2586573469 @default.
• W2539341441 hasRelatedWork W2979317294 @default.
• W2539341441 hasRelatedWork W2979433572 @default.

• next